Results 91 to 100 of about 49,482 (293)
Generation and functional comparison of anti-CD20 chimeric antigen receptors
, 2019 Chimeric antigen receptor (CAR) T-cell therapy has proven effective, particularly in targeting relapsed, refractory haematological malignancies. However, optimal CAR design is not fully understood. It is known that the antigen epitope position, affinity of interaction and the length of the CAR construct can all impact function, but these factors often ...
openaire +2 more sources
Advanced Science, EarlyView.CD20⁺FCRL4⁺ B cells in nasopharyngeal carcinoma actively cross‐present exogenous tumor antigens via MHC‐I, enhancing CD8⁺ T‐cell activation, memory formation, and cytotoxicity. IFNγ‐driven WDFY4 upregulation facilitates this process. These findings reveal an unconventional B‐cell–mediated antitumor mechanism and indicate potential relevance to ...
Benjian Zhang +17 more
wiley +1 more source
Infectious agents is a risk factor for myxomatous mitral valve degeneration: A case control study
BMC Infectious Diseases, 2017 Background The etiology of myxomatous mitral valve degeneration (MVD) is not fully understood and may depend on time or environmental factors for which the interaction of infectious agents has not been documented.
Marcos Gradim Tiveron +8 more
doaj +1 more source
Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives [PDF]
, 2010 Monoclonal antibodies have been the most successful therapeutics ever brought to cancer treatment by immune technologies. The use of monoclonal antibodies in B-cell Non-Hodgkin's lymphomas (NHL) represents the greatest example of these advances, as the ...
Alessio Nencioni +6 more
core +2 more sources
Advanced Science, EarlyView.The schematic illustration of the MHSCG platform for spatiotemporal responsive GRb1 release to induce androgen deprivation therapy (ADT) and immunogenic cell death (ICD) multimodal therapy in prostate cancer. Abstract Metal‐based immunotherapy represents a promising strategy for enhancing antitumor efficacy; however, its clinical application is limited
Rui Zan +13 more
wiley +1 more source
Case Reports in Hematology, 2016 Diffuse large B-cell lymphoma (DLBCL) is a neoplasm of large B-lymphocytes with a diffuse growth pattern. The neoplastic cells express B-cell markers such as CD20 and PAX-5 and there may be coexpression of BCL-2, BCL-6, CD10, and MUM-1.
Elham Vali Betts, Hooman H. Rashidi
doaj +1 more source
Predicting the efficacy of anti-B-cell therapy in patients with multiple sclerosis [PDF]
Анналы клинической и экспериментальной неврологииIntroduction. Prognostic markers can be used to evaluate a response to anti-B-cell therapy in patients with multiple sclerosis (MS). Aim. The study aimed to evaluate the characteristics of peripheral blood (PB) lymphocytes and monocytes in patients ...
Yuliana A. Belova +2 more
doaj +1 more source
HHV8-Negative Primary Effusion Lymphoma of B-Cell Lineage: Two Cases and a Comprehensive Review of the Literature [PDF]
, 2013 Primary effusion lymphoma (PEL) is a rare extranodal lymphoma that typically presents in a body cavity in the absence of a detectable tumor mass and that occurs predominantly in immunosuppressed individuals.
Grohs, Heinz K. +5 more
core +3 more sources
, 2023 <div>Abstract<p>The adoptive transfer of T cells expressing anti-CD19 chimeric antigen receptors (CARs) has shown remarkable curative potential against advanced B-cell malignancies, but multiple trials have also reported patient relapses due to the emergence of CD19-negative leukemic cells.
Yvonne Y. Chen +4 more
openaire +1 more source
Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment
Advanced Science, EarlyView.This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang +7 more
wiley +1 more source